registrieren | anmelden | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

worx11s oncology [19 articles]

Neue Publikationen in worx11s Bibliothek eingetragen unter dem Bezeichner: oncology. You can also see everyone's oncology.
  • Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.
    Cancer, Vol. 110, No. 7. (20 August 2007), pp. 1621-1628.
    by David R R Buchanan, Ann M M O'mara, Joseph W W Kelaghan, Maria Sgambati, Worta McCaskill-Stevens, Lori Minasian
    posted to bm oncology quality quality_of_life by worx11 on 2007-09-21 17:19:50 as ** along with 1 person and 1 group suizan XROWXR
  • Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    Clin Ther, Vol. 27, No. 8. (August 2005), pp. 1295-1310.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:23:29 as ** along with 1 group XROWXR
  • Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    Support Care Cancer, Vol. 13, No. 12. (December 2005), pp. 975-986.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:21:31 as ** along with 1 group XROWXR
  • The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy.
    Am J Health Syst Pharm, Vol. 64, No. 15 Suppl 10. (1 August 2007)
    by C Downs
    posted to bm medicare medicare_part_d oncology by worx11 on 2007-09-20 20:17:29 as ** along with 1 group XROWXR
  • Formulary issues at a pediatric hospital: experience at Children's National Medical Center.
    Hosp Formul, Vol. 26, No. 6. (June 1991), pp. 500-510.
    by GJ Cohen, SJ Allen
    posted to bm formulary oncology outcomes by worx11 on 2007-09-20 20:14:23 as ** along with 1 group XROWXR
  • Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    J Clin Oncol, Vol. 25, No. 18. (20 June 2007)
    by E Low,
    posted to bm oncology outcomes by worx11 on 2007-09-20 20:11:50 as ** along with 1 group XROWXR
  • European perspective on the costs and cost-effectiveness of cancer therapies.
    J Clin Oncol, Vol. 25, No. 2. (10 January 2007), pp. 191-195.
    by MF Drummond, AR Mason
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:08:00 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Br J Cancer, Vol. 89, No. 4. (18 August 2003), pp. 634-640.
    by A Gordois, P Scuffham, E Warren, S Ward
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:30:11 as ** along with 1 group XROWXR
  • Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Health Technol Assess, Vol. 8, No. 28. (July 2004)
    by K Dalziel, A Round, K Stein, R Garside, A Price
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:43 as ** along with 1 group XROWXR
  • Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Pharmacoeconomics, Vol. 23, No. 5. (2005), pp. 515-526.
    by K Dalziel, A Round, R Garside, K Stein
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:07 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Clin Ther, Vol. 26, No. 11. (November 2004), pp. 1924-1933.
    by E Warren, S Ward, A Gordois, P Scuffham
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:25:17 as ** along with 1 group XROWXR
  • Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Clin Ther, Vol. 26, No. 9. (September 2004), pp. 1546-1561.
    by M Marchetti, M Caruggi, G Colombo
    posted to bm budget_impact cost-utility oncology outcomes by worx11 on 2007-09-20 19:23:02 as ** along with 1 group XROWXR
  • Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Clin Drug Investig, Vol. 27, No. 2. (2007), pp. 85-93.
    by DM Huse, M von Mehren, G Lenhart, H Joensuu, C Blanke, W Feng, S Finkelstein, G Demetri
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:21:12 as ** along with 1 person and 1 group Terkko XROWXR
  • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Clin Breast Cancer, Vol. 7, No. 8. (June 2007), pp. 608-618.
    by TE Delea, J Karnon, O Sofrygin, SK Thomas, NL Papo, V Barghout
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:18:02 as ** along with 1 group XROWXR
  • Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Pharmacoeconomics, Vol. 24, No. 3. (2006), pp. 237-250.
    by J Karnon, T Delea, SR Johnston, R Smith, J Brandman, J Sung, PE Goss
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:16:06 as ** along with 1 group XROWXR
  • Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Am J Clin Oncol, Vol. 26, No. 3. (June 2003), pp. 289-296.
    by G Dranitsaris, S Verma, M Trudeau
    posted to bm cost-utility oncology by worx11 on 2007-09-20 19:15:12 as ** along with 1 group XROWXR
  • Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Breast, Vol. 16, No. 3. (June 2007), pp. 252-261.
    by C Skedgel, D Rayson, R Dewar, T Younis
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:02:57 as ** along with 1 group XROWXR
  • Reimbursement for cancer treatment: coverage of off-label drug indications.
    J Clin Oncol, Vol. 24, No. 19. (1 July 2006), pp. 3206-3208.
    by
    posted to bm oncology by worx11 on 2007-09-20 18:57:10 as ** along with 1 group XROWXR
  • Cost considerations in the management of cancer in the older patient.
    Oncology (Williston Park), Vol. 21, No. 7. (June 2007)
    by JM McKoy, KA Fitzner, BJ Edwards, M Alkhatib, CC Tigue, NJ Nonzee, CR Bolden, CL Bennett
    posted to bm oncology outcomes by worx11 on 2007-09-20 18:54:02 as ** along with 1 group XROWXR
    • Bemerkung: Sie können diese Seite wie folgt zitieren: http://www.citeulike.org/user/worx11/tag/oncology

    RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.